Compare ServiceNow Inc (NOW) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ServiceNow Inc vs Tango Therapeutics Inc. — how do they compare? ServiceNow Inc trades at $139.51 (market cap $143.30B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: ServiceNow Inc is far larger — about 38.2× Tango Therapeutics Inc.'s market cap, and ServiceNow Inc is more actively traded (13,207,010 versus 9,619,106). Which is the better fit depends on your goals — on Pluang, investors hold ServiceNow Inc for 54 Days and Tango Therapeutics Inc. for 0 Days on average.
| NOW | TNGX | |
|---|---|---|
Market Cap | $143.30B | $3.75B |
Volume | 13,207,010 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $189.26 | $32.90 |
52-Week Low | $83.00 | $7.50 |
Typical Hold Time | 54 Days | 0 Days |
Enterprise Value | $147.09B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ServiceNow (NOW) trades at $138.61, down 1.22% on the day, amid a bullish technical setup with strong analyst support. The stock shows robust fundamentals with revenue growth from $7.2B in 2022 to $13.3B in 2025, a high gross margin of 74.77%, and consistent earnings beats. Recent news highlights AI-driven momentum, with AI annual contract value surpassing $1B in Q2 2026, fueling positive sentiment despite premium valuations.
The outlook remains positive given AI adoption and earnings strength, but risks include stiff competition and high P/E of 86.63. With 87% of analysts rating it Buy and a consensus target of $150.74, the stock offers upside, though investors should weigh valuation concerns against growth prospects.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ServiceNow Inc
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
